These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29878859)

  • 41. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction.
    Schürmann W; Schmidtmann S; Moroni P; Massey D; Qidan M
    Treat Respir Med; 2005; 4(1):53-61. PubMed ID: 15725050
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy.
    González-Torralba F; Baloira A; Abad A; Fuster A; García-Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1005-1015. PubMed ID: 35547784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of gamma scintigraphy to evaluate the performance of new inhalers.
    Newman SP
    J Aerosol Med; 1999; 12 Suppl 1():S25-31. PubMed ID: 10623338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fenoterol delivery by Respimat soft mist inhaler versus CFC metered dose inhaler: cumulative dose-response study in asthma patients.
    Vincken W; Dewberry H; Moonen D
    J Asthma; 2003 Sep; 40(6):721-30. PubMed ID: 14580004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Practical problems with aerosol therapy in COPD.
    Rau JL
    Respir Care; 2006 Feb; 51(2):158-72. PubMed ID: 16441960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma.
    von Berg A; Jeena PM; Soemantri PA; Vertruyen A; Schmidt P; Gerken F; Razzouk H
    Pediatr Pulmonol; 2004 Mar; 37(3):264-72. PubMed ID: 14966821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advancement of a Positive-Pressure Dry Powder Inhaler for Children: Use of a Vertical Aerosolization Chamber and Three-Dimensional Rod Array Interface.
    Farkas D; Bonasera S; Bass K; Hindle M; Longest PW
    Pharm Res; 2020 Aug; 37(9):177. PubMed ID: 32862295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients.
    Kunkel G; Magnussen H; Bergmann K; Juergens UR; de Mey C; Freund E; Hinzmann R; Beckers B
    Respiration; 2000; 67(3):306-14. PubMed ID: 10867600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler.
    Kemp JP; Hill MR; Vaughan LM; Meltzer EO; Welch MJ; Ostrom NK
    Ann Allergy Asthma Immunol; 1997 Oct; 79(4):322-6. PubMed ID: 9357377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhalation of tobramycin using simulated cystic fibrosis patient profiles.
    Haynes A; Geller D; Weers J; Ament B; Pavkov R; Malcolmson R; Debonnett L; Mastoridis P; Yadao A; Heuerding S
    Pediatr Pulmonol; 2016 Nov; 51(11):1159-1167. PubMed ID: 27133552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The History of Therapeutic Aerosols: A Chronological Review.
    Stein SW; Thiel CG
    J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):20-41. PubMed ID: 27748638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro-in vivo correlations (IVIVCs) of deposition for drugs given by oral inhalation.
    Newman SP; Chan HK
    Adv Drug Deliv Rev; 2020 Dec; 167():135-147. PubMed ID: 32593641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
    Son YJ; Worth Longest P; Hindle M
    Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Respimat
    Iwanaga T; Tohda Y; Nakamura S; Suga Y
    Clin Drug Investig; 2019 Nov; 39(11):1021-1030. PubMed ID: 31377981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experimental Study of Spiriva Respimat Soft Mist Inhaler Spray Characterization: Size Distributions and Velocity.
    Alatrash A; Mehri R; Ogrodnik N; Matida E; Fiorenza F
    J Aerosol Med Pulm Drug Deliv; 2019 Oct; 32(5):293-302. PubMed ID: 31259646
    [No Abstract]   [Full Text] [Related]  

  • 58. Development of Dry Powder Inhaler Patient Interfaces for Improved Aerosol Delivery to Children.
    Bass K; Longest W
    AAPS PharmSciTech; 2020 May; 21(5):157. PubMed ID: 32451773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The inhalation of drugs: advantages and problems.
    Rau JL
    Respir Care; 2005 Mar; 50(3):367-82. PubMed ID: 15737247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of ramp-up of inspired airflow on in vitro aerosol dose delivery performance for certain dry powder inhalers.
    Ung KT; Chan HK
    Eur J Pharm Sci; 2016 Mar; 84():46-54. PubMed ID: 26780380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.